SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized ...
A new study led by researchers at the University of Liège highlights the unexpected role of Stard7 in the development of intestinal cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results